High FCF Margin Stocks in Health Care
Companies converting more than 10% of revenue into free cash flow, demonstrating efficient cash generation.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
51 Companies Meeting Criteria
Showing 1–50 of 51 companies, ranked by FCF Margin.
| # | Company | FCF Margin | Free Cash Flow |
|---|---|---|---|
| 1 | MGTXMeiraGTx Holdings plc | 83.2% | -$109M |
| 2 | NKTRNEKTAR THERAPEUTICS | 59.0% | -$209M |
| 3 | KRYSKrystal Biotech, Inc. | 48.5% | $189M |
| 4 | INVAInnoviva, Inc. | 47.6% | $196M |
| 5 | HALOHalozyme | 46.2% | $645M |
| 6 | IRWDIRONWOOD PHARMACEUTICALS INC | 42.9% | $127M |
| 7 | ABCLAbCellera Biologics Inc. | 42.6% | -$174M |
| 8 | COLLCollegium Pharmaceutical, Inc. | 42.0% | $328M |
| 9 | AGIOAGIOS PHARMACEUTICALS, INC. | 41.0% | -$377M |
| 10 | PTCTPTC Therapeutics, Inc. | 40.6% | $702M |
| 11 | HRMYHarmony Biosciences Holdings, Inc. | 40.1% | $348M |
| 12 | RGENRepligen | 39.2% | $94M |
| 13 | EXELExelixis | 37.8% | $876M |
| 14 | DNLIDenali Therapeutics Inc. | 36.2% | -$422M |
| 15 | CPRXCatalyst Pharmaceuticals Partners, Inc. | 35.4% | $209M |
| 16 | UTHRUnited Therapeutics | 32.7% | $1.0B |
| 17 | ALKSAlkermes plc | 32.6% | $480M |
| 18 | GILDGilead Sciences | 32.1% | $9.5B |
| 19 | JAZZJazz Pharmaceuticals | 30.4% | $1.3B |
| 20 | ABBVAbbVie | 29.1% | $17.8B |
| 21 | REGNRegeneron Pharmaceuticals | 28.4% | $4.1B |
| 22 | BMYBristol Myers Squibb | 26.7% | $12.8B |
| 23 | VRTXVertex Pharmaceuticals | 26.6% | $3.2B |
| 24 | NBIXNeurocrine Biosciences | 26.2% | $749M |
| 25 | STOKStoke Therapeutics, Inc. | 24.3% | $45M |
| 26 | ZTSZoetis | 24.1% | $2.3B |
| 27 | BMRNBioMarin Pharmaceutical | 22.5% | $725M |
| 28 | AMGNAmgen | 22.0% | $8.1B |
| 29 | DVAXDynavax Technologies Corp. | 21.7% | $60M |
| 30 | PBHPrestige Consumer Healthcare | 21.3% | $239M |
| 31 | EBSEmergent BioSolutions Inc. | 21.1% | $157M |
| 32 | JNJJohnson & Johnson | 20.9% | $19.7B |
| 33 | BIIBBiogen | 20.7% | $2.1B |
| 34 | KNSAKiniksa Pharmaceuticals International, plc | 20.1% | $136M |
| 35 | URGNUroGen Pharma Ltd. | 19.9% | -$163M |
| 36 | ANIPANI Pharmaceuticals, Inc. | 19.4% | $171M |
| 37 | MRKMerck & Co. | 19.0% | $12.4B |
| 38 | ARWRArrowhead Pharmaceuticals | 18.9% | $157M |
| 39 | PCRXPacira BioSciences, Inc. | 18.8% | $137M |
| 40 | CORTCorcept Therapeutics Incorporated | 18.6% | $142M |
| 41 | LGNDLigand Pharmaceuticals, Inc. | 18.2% | $49M |
| 42 | ONCBeOne Medicines Ltd. | 17.6% | $942M |
| 43 | AMPHAmphstar Pharmaceuticals, Inc. | 16.8% | $121M |
| 44 | CAPRCAPRICOR THERAPEUTICS, INC. | 16.6% | -$73M |
| 45 | HROWHARROW, INC. | 15.8% | $43M |
| 46 | SPRYARS Pharmaceuticals, Inc. | 14.6% | -$171M |
| 47 | PFEPfizer | 14.5% | $9.1B |
| 48 | VTRSViatris | 13.6% | $1.9B |
| 49 | ALNYALNYLAM PHARMACEUTICALS, INC. | 12.5% | $465M |
| 50 | MIRMMirum Pharmaceuticals, Inc. | 10.5% | $55M |
Understanding FCF Margin
An FCF margin above 10% means a company converts more than 10 cents of every revenue dollar into free cash. This signals capital-light operations and strong pricing power. Technology and pharmaceutical companies often lead in FCF margin due to low physical capital requirements.
FCF Margin > 10%
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics